Clinical Trial

Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE

Study acronym: PATH STROKE C
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The objective of this clinical trial is to evaluate the efficacy and safety of platelet aggregation function - guided precision anti - platelet therapy in patients with acute cerebral infarction. The main question it aims to answer is: among the cerebral infarction patients with possible clopidogrel resistance detected by platelet aggregation function tests, what is the efficacy and safety of using ticagrelor to replace the clopidogrel treatment regimen.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-28; most recent amendment 2026-05-11.
Status change: Not Yet Recruiting → Recruiting 2026-01-16
Trial Details
NCT Number NCT06853535
Lead Sponsor Sichuan Provincial People's Hospital
Collaborators: Fudan University, Chengdu Medical College
Conditions Acute Ischemic Stroke, Clopidogrel Resistance
Enrollment 5,138 participants
Start Date 2025-05-23
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-12